doxazosin has been researched along with Inflammation in 7 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the anti-inflammatory effects of doxazosin in rodent models of inflammation." | 7.79 | Novel anti-inflammatory effects of doxazosin in rodent models of inflammation. ( Cheung, PH; Ciallella, J; Saha, S; Tung, D, 2013) |
| "To evaluate the influence of doxazosin and finasteride on histologic findings in benign prostatic hyperplasia accompanied by prostatitis, and to examine the factors related with prostate carcinogenesis." | 7.74 | Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. ( Park, DS; Shim, JY, 2008) |
| "Nitrites/nitrates were significantly lower (P < 0." | 6.72 | Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, R; Galli, S; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Salvadeo, S; Tinelli, C, 2006) |
| " We examined the contribution of the angiotensin-converting enzyme inhibitor ramipril and the alpha 1-adrenergic receptor blocker doxazosin on blood pressure and on markers of inflammation and hemostasis in 59 individuals with mild-to-moderate hypertension randomized to receive double-blind ramipril 10 mg od or doxazosin 8 mg od for 12 weeks." | 5.27 | Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension. ( Ekholm, M; Gigante, B; Jekell, A; Kahan, T; Wallén, NH, 2018) |
| "To examine the anti-inflammatory effects of doxazosin in rodent models of inflammation." | 3.79 | Novel anti-inflammatory effects of doxazosin in rodent models of inflammation. ( Cheung, PH; Ciallella, J; Saha, S; Tung, D, 2013) |
| "To evaluate the influence of doxazosin and finasteride on histologic findings in benign prostatic hyperplasia accompanied by prostatitis, and to examine the factors related with prostate carcinogenesis." | 3.74 | Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. ( Park, DS; Shim, JY, 2008) |
| "Nitrites/nitrates were significantly lower (P < 0." | 2.72 | Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, R; Galli, S; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Salvadeo, S; Tinelli, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Asfuroglu, A | 1 |
| Balci, M | 1 |
| Aslan, Y | 1 |
| Senel, C | 1 |
| Guzel, O | 1 |
| Kilinckaya, MF | 1 |
| Turhan, T | 1 |
| Tuncel, A | 1 |
| Ekholm, M | 1 |
| Jekell, A | 1 |
| Wallén, NH | 1 |
| Gigante, B | 1 |
| Kahan, T | 1 |
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Morant, S | 1 |
| Jiang, B | 1 |
| Cruickshank, JK | 1 |
| Webb, AJ | 1 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Sun, X | 2 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 1 |
| Wang, W | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Li, X | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Li, T | 1 |
| Yang, S | 1 |
| She, X | 1 |
| Yan, Q | 1 |
| Zhang, P | 1 |
| Zhu, H | 1 |
| Wang, F | 1 |
| Luo, X | 1 |
| Park, DS | 1 |
| Shim, JY | 1 |
| Tung, D | 1 |
| Ciallella, J | 1 |
| Cheung, PH | 1 |
| Saha, S | 1 |
| Derosa, G | 1 |
| Cicero, AF | 1 |
| D'Angelo, A | 1 |
| Tinelli, C | 1 |
| Ciccarelli, L | 1 |
| Piccinni, MN | 1 |
| Pricolo, F | 1 |
| Salvadeo, S | 1 |
| Montagna, L | 1 |
| Gravina, A | 1 |
| Ferrari, I | 1 |
| Galli, S | 1 |
| Paniga, S | 1 |
| Fogari, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| On the Antithrombotic Effects of Doxazosin and Ramipril in Essential Hypertension[NCT02901977] | Phase 4 | 71 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for doxazosin and Inflammation
| Article | Year |
|---|---|
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti | 2018 |
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; C-Reactive Protein; Doxazosin; Female; H | 2006 |
4 other studies available for doxazosin and Inflammation
| Article | Year |
|---|---|
What Is the Interaction between Urine C-Reactive Protein, Prostatic Inflammation, and Doxazosin Treatment in Patients with Benign Prostatic Hyperplasia? A Pilot Study.
Topics: Adrenergic alpha-Antagonists; Aged; C-Reactive Protein; Doxazosin; Humans; Inflammation; Male; Middl | 2022 |
Modulation of α-adrenoceptor signalling protects photoreceptors after retinal detachment by inhibiting oxidative stress and inflammation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Apoptosis; Di | 2019 |
Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antihypertensive A | 2008 |
Novel anti-inflammatory effects of doxazosin in rodent models of inflammation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Chemokine CCL2; Disease | 2013 |